Intensity Therapeutics Enrolls Patients in INVINCIBLE-3 and INVINCIBLE-4
Intensity Therapeutics resumed patient enrollment in two key oncology studies, INVINCIBLE-3 for soft tissue sarcoma and INVINCIBLE-4 for TNBC. The company reported $8.5 million in cash as of September 30, 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed